Additionally, studies indicate that higher levels of methylation within the MGMT promoter region are associated with improved overall survival rates in GBM patients, underscoring the need for routine assessment of MGMT status in neuro-oncology [16, 58, 59]. This evidence concerns the gene MGMT and glioblastoma.